RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > Including Regulatory at the Strategy Table

Including Regulatory at the Strategy Table

Posted 01 December 2010 | By

Transforming a controlled stream of high-quality raw materials into a steady output of products that delight an ever-increasing number of customers is the ultimate goal of any manufacturer. It becomes more critical in highly regulated businesses such as the pharmaceutical and medical device industries. Regulations provide frameworks intended to manage the constant tensions between attaining quality and containing costs. When done correctly, production can maintain a balance between quality and cost such that efficiencies lead to sustainable savings. In turn, those sustainable savings can fuel the development of capabilities to increase volume and diversity of product offerings. Within FDAregulated industries, this cycle of product flow must accommodate a growing number of regulatory requirements that are also increasing in complexity and scope. This is creating the downward spiral that is hindering many companies.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe

Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.